Navegando por Assunto "Homeopatia"

Agora exibindo 1 - 2 de 2

Acesso aberto (Open Access)
Avaliação do efeito antigenotóxico e anticitotóxico do bioproduto método CANOVA®
(Universidade Federal do Pará, 2012-09-28) NASCIMENTO, Henrique Fonseca Sousa do; BAHIA, Marcelo de Oliveira; http://lattes.cnpq.br/3219037174956649
The CANOVA® (CA) method is a Brazilian homeopathic immunomodulator. CA is indicated in clinical conditions where the immune system is impaired. N-Methyl-Nnitrosourea (NMU) is an N-nitroso carcinogenic alkylating agent used as an experimental model in rodents and monkeys. NMU also shows genotoxic/mutagenic effects that can be assessed by classical tests such as detection of DNA damage and chromosomal aberrations. Although several studies have shown promising results in the use of CA, there are no studies reporting possible antigenotoxic effects of this medicine, despite its anticancer potential. Therefore, the present study evaluated the in vitro antigenotoxic and anticytotoxic effects of CA in human lymphocytes exposed to NMU. Samples of human lymphocytes that were subjected to different concentrations of a mixture containing CA and NMU were used in the present study. The viability of cells exposed to NMU was evaluated by MTT assay, CA genotoxicity/antigenotoxicity was evaluated by the comet assay and CA anticytotoxicity was assessed by quantification of apoptosis and necrosis using fluorescent dyes (acridine orange/ethidium bromide). The MTT assay showed that NMU was able to decrease lymphocyte viability significantly. By using the comet assay it was observed that CA significantly reduces DNA damage induced by NMU, which sets a clear antigenotoxic effect of the homeopathic compound. CA also reduced significantly the frequency of NMU-induced apoptosis after 24 hours of treatment. We conclude that CA had an antigenotoxic and anticytotoxic effect in the conditions evaluated in this study, thereby demonstrating a clear cytoprotective potential.
Acesso aberto (Open Access)
Avaliação do perfil da resposta celular observado em indivíduos da espécie Cebus apella expostos ao carcinógeno N-Metil-N-nitrosuréia (mnu) e tratados com o modificador da resposta imune canova®
(Universidade Federal do Pará, 2011-04-19) FEIO, Danielle Cristinne Azevedo; BRITO JÚNIOR, Lacy Cardoso de; http://lattes.cnpq.br/9705670940390281; LIMA, Patrícia Danielle Lima de; http://lattes.cnpq.br/3411620003450812
The Immune response modifier Canova® (CA) is a homeopathic drug indicated for patients with a depressed immune system, once this medicine appears to increase the innate immunity and induce an immune response against multiple and severe pathological conditions, including Neoplasms. This increase of innate immunity is due to its involvement in the proliferation and differentiation of hematopoietic cells and mononuclear differentiation induction in bone marrow cells. The chemical compound N-Methyl-N-Nitrosourea (MNU) is a alkylating agent powerful carcinogenic able to cause mutations, chromosomal aberrations and DNA methylation, that induce the imbalance in the defense system of the cell and thus stop mechanisms related to cellular metabolism. This compound has been widely used in the induction of experimental tumors. The goal of this work is to assess the pattern of hematopoietic cell response in Cebus apella primate species exposed to carcinogenic N-Methyl-N-Nitrosourea (MNU) and subjected to the treatment with the Immune response modifier Canova®, through the analysis of biochemical, haematological, immune and cell cycle. We had used 13 (thirteen) adult animals of the species Cebus apella divided into five main groups: the control (negative and positive) and experimental (composed of three subgroups). The first experimental group received the MNU during thirty-five days, the second received treatment with Canova during three days, and the third received the MNU during 35 days and the end of this period received treatment with Canova during three days. Evaluation of cellular immune response was through immunophenotyping (CD3, CD4, CD8, T, B, NK) and complete blood count, liver and kidney function through biochemical analysis (ALT, AST, GGT, urea and creatinine) and kinetic evaluation of cell cycle by flow cytometry. Analysis of haematological values of hemoglobin, hematocrit and red blood cells of positive control groups performed significantly lower when compared to the negative control groups, demonstrating an anemia, while the increased white lineage cells in these groups is probably due to the animal's inflammatory response to neoplastic process. The increase of leukocytes has also been observed in experimental groups treated with the CA, a fact explained by the action of this drug, which acts as a modifier of immune response. Although it has been reported that CA can act by increasing the number of neutrophils, in this study we did not observe this action of the medicinal product, probably by the short time of treatment. Monocytes were decreased in the group treated with MNU and risen in groups that received CA probably by drug act in the activation of macrophages via stimulation of monocytes. In biochemical analysis, urea and creatinine were changed in the groups that received the MNU acutely, these changes, as well as those found in the analysis of liver enzymes, can be associated with typical symptoms of poisoning by carcinogenic drugs. Analysis of cell cycle kinetics of animals treated with CA, there had been a significant increase in cell G0-G1 as well as the percentage of cells in cellular proliferation stage (stageG2-M). We found that CA had minimized the toxicity of the MNU in certain haematological and biochemical, we had observed their partially skill to modify immune response, as improve white blood cell count, but without changing the pattern of immunological markers. Then CA is able to restore some hematopoietic system components and can act as an adjuvant in chemotherapy treatments.